<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01472692</url>
  </required_header>
  <id_info>
    <org_study_id>110806</org_study_id>
    <nct_id>NCT01472692</nct_id>
  </id_info>
  <brief_title>Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure</brief_title>
  <official_title>Treatment of Uric Acid With the Xanthine Oxidase Inhibitor Febuxostat: Effects on Blood Pressure, Metabolic Markers, and Aortic Stiffness in Prehypertensive</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High normal blood pressure, also called prehypertension, is a significant problem. High uric
      acid in the blood, the same thing that causes gout, may cause higher blood pressures. The
      investigators plan to monitor the effects of the drug febuxostat(trade name Uloric) on blood
      pressure and stiffness of the main blood vessels and see if lowering uric acid has any
      effect.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in 24 hour blood pressure</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Pulse wave velocity</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Prehypertension</condition>
  <condition>Gout</condition>
  <condition>Pulse Wave Velocity</condition>
  <condition>Hypertension</condition>
  <condition>24 Hour Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Febuxostat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>80mg PO daily for 8 weeks</description>
    <arm_group_label>Febuxostat</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Uloric</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prehypertensive male and female subjects with SBP =120-140 mmHg or DBP =80-90 mmHg (as
             determined by seated office BP).

          -  Plasma uric acid level â‰¥5 mg/dl

          -  Ages 18-50

          -  non-smokers

          -  Subjects will need to remain in the San Diego area for the duration of the study and
             be accessible by telephone or email.

        Exclusion Criteria:

          -  no current smoking in the prior 6 months.

          -  Any history of any serious medical conditions requiring close monitoring from
             physicians- such as liver impairment, chronic kidney disease, or diabetes mellitus.
             Participants not currently under the care of a physician for these conditions will be
             eligible for the study.

          -  Any history of gout, hypertension, hypercholesterolemia, morbid obesity.

          -  Any history of use xanthine oxidase inhibitors, antihypertensives, antiglycemic, and
             cholesterol lowering medications

          -  any history of illicit drug use within the last 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel O'Connor, UCSD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jason T. Davis, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univerisity Of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2011</study_first_submitted>
  <study_first_submitted_qc>November 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2011</study_first_posted>
  <last_update_submitted>March 31, 2014</last_update_submitted>
  <last_update_submitted_qc>March 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Daniel O'Connor</investigator_full_name>
    <investigator_title>M.D. Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Prehypertension</keyword>
  <keyword>Gout</keyword>
  <keyword>Puls Wave Velocity</keyword>
  <keyword>Hypertension</keyword>
  <keyword>24 hour blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Prehypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

